We aimed to determine if successful or failed eradication of Helicobacter pylori with triple therapy causes any difference in gastric mucosal histology. Japanese H. pyloripositive patients with a healed peptic ulcer received high (n = 112) or low (n = 113) doses of triple therapy (omeprazole, amoxicillin and clarithromycin) for 1 week. Biopsies from the greater curvature of the central antrum and upper corpus were taken 6 weeks and 30 weeks after treatment completion, and gastric mucosal histology compared between successful (n = 171) and failed (n = 34) eradication groups. Morphological variables of gastritis were graded according to the updated Sydney System. Successful eradication therapy was defined as improvement in inflammation, neutrophil activity and atrophy; failed eradication therapy as improvement in inflammation and neutrophil activity only. Gastric mucosal atrophy gradually improved (in addition to improvements in inflammation and neutrophil activity) with successful eradication of H. pylori infection.
Introduction
Since the discovery of Helicobacter pylori in the stomach in 1983, 1 much research has focused on the relationship between H. pylori infection and gastrointestinal disorders. Subsequent studies have demonstrated that H. pylori infection is involved in the relapse of peptic ulcer, 2 -4 prompting the US National Institutes of Health Consensus Conference 5 to recommend that H. pylori eradication therapy be undertaken at both onset and relapse of peptic ulcer. This recommendation resulted in the investigation of various H. pylori eradication regimens. Reports from western countries have demonstrated the effectiveness of triple eradication therapies combining a proton pump inhibitor with two antibacterial agents. 6 -9 The efficacy and safety of one triple therapy regimen has also been assessed in Japanese patients. 10 Since the attainment of high H. pylori eradication rates, attention has turned to the histological changes observed in H. pylori gastritis. Atrophy of the gastric native epithelium and intestinal metaplasia are of particular interest, due to their known involvement in the aetiology of gastric cancer. 11 -14 In this study, which is part of a larger study examining the efficacy and tolerability of triple therapy in Japanese patients, the effect of H. pylori eradication treatment on gastric mucosal histology was assessed following triple therapy with omeprazole, amoxicillin and clarithromycin for 1 week. Histological changes were determined using the updated Sydney System, 15 and differences in histology between patients successfully treated and those in whom H. pylori was not eradicated were analysed. Peptic ulcer relapse rate was assessed 6 months after completion of therapy; these results will be published separately.
Patients and methods
The study was carried out in compliance with Good Clinical Practice for Trials on Drugs (GCP; Japanese ministerial ordinance no. 28, issued 27 March 1997) and the Helsinki Declaration (South Africa revision, 1996). Approval for the study was received from the Institutional Review Boards of all participating centres and all patients gave written informed consent.
PATIENTS
Japanese patients aged ≥ 20 years, who were shown to be H. pylori-positive by both rapid urease test and culture, and who visited a participating institution between May 2000 and July 2000, were recruited to the study. Endoscopy revealed a healed peptic ulcer in all cases.
HELICOBACTER PYLORI ERADICATION THERAPY
As part of the wider study, patients were randomized to receive low-dose (omeprazole 40 mg/day + amoxicillin 1500 mg/day + clarithromycin 800 mg/day) or high-dose (omeprazole 40 mg/day + amoxicillin 2000 mg/day + clarithromycin 1000 mg/day) eradication therapy. Both regimens were administered for 1 week.
EFFICACY OF THERAPY
Six weeks after completion of eradication therapy, the presence or absence of H. pylori was determined by bacterial culture, histological evaluation (see next section), and 13 C-urea breath test.
Patients who were H. pylori-negative were classified as having 'successful eradication', while those who remained H. pylori-positive were classified as having 'failed eradication'.
HISTOLOGICAL EVALUATION
Biopsy specimens were taken from the greater curvature of the central antrum and the greater curvature of the upper corpus, before treatment and 6 weeks and 30 weeks after completion of the treatment. Histological evaluation of H. pylori status was performed on haematoxylin and eosinstained sections, and H. pylori-immunostained sections of the biopsy specimens.
The severity of inflammation, neutrophil activity, atrophy and metaplasia was graded as 'normal', 'mild', 'moderate' or 'marked', according to the updated Sydney System. 15 'Judgement impossible' was recorded if histological changes could not be graded.
STATISTICAL EVALUATION
The severity of inflammation, neutrophil activity, atrophy and metaplasia were compared between patients on whom data were collected at all three assessment time points. The severity of the histopathological findings determined 6 weeks and 30 weeks after completion of treatment was compared with that determined prior to eradication therapy.
Histological outcome was not expected to be identical between the successful and failed eradication groups, even without eradication therapy, so rigorous statistical testing was not performed. Descriptive statistics were, however, used to present the histological changes.
Results

PATIENT POPULATION
Two hundred and twenty-five patients were recruited to the study, and 113 and 112 were randomized to the low and high-dose groups, respectively. Five patients were withdrawn from the study due to adverse effects, four were unavailable for follow-up, and two were lost to follow-up. A total of 214 patients completed the study, and biopsy specimens were taken at all three assessment time points from 205 patients (101 and 104 in the low and high-dose groups, respectively). Not all specimens, however, were evaluable.
There were no differences in gastric histology between the high and low-dose groups. The eradication rate was 78.8% (95% confidence interval: 70.1 -85.9%) for the low-dose group and 83.0% (95% confidence interval: 74.8 -89.5%) for the high-dose group, which indicated no clinically significant difference between the regimens.
One hundred and seventy-one patients had successful eradication, while 34 had failed eradication. The characteristics of patients providing evaluable specimens are shown in Table 1 .
The only notable difference in patient characteristics between the successful and failed eradication groups was a higher rate of gastric ulcer in the latter.
The mean ± SD observation period was 224.9 ± 8.2 days in the successful eradication group and 225.0 ± 7.8 days in the failed eradication group.
INFLAMMATION
In both the successful and failed eradication groups, inflammation at 6 weeks and 30 weeks after treatment completion was markedly less severe compared with before therapy (Fig. 1 ). In the successful eradication group, the proportion of patients with moderate or marked inflammation in the central antrum and upper corpus decreased from 80% and 46% before treatment, to 3% and 0% at 6 weeks after treatment completion, respectively. The corresponding figures in the failed eradication group were 65% and 52% before treatment, and 27% and 12% at 6 weeks, respectively.
NEUTROPHIL ACTIVITY
Neutrophil activity at 6 weeks and 30 weeks after completion of treatment was less severe in both groups compared with before therapy (Fig. 2) . In the successful eradication group, the proportion of patients with moderate or marked neutrophil activity in the central antrum and upper corpus was 36% and 35% before treatment, respectively. All patients achieved complete resolution of neutrophil activity at both sites after 6 weeks. Mild neutrophil activity was observed in four patients (2.4%) whose H. pylori status at 30 weeks had reverted to positive. In the failed eradication group, the proportion of patients with moderate or marked neutrophil activity in the central antrum and upper corpus decreased from 27% and 46% before treatment to 12% and 3% at 6 weeks, respectively. The improvement in neutrophil activity observed in the failed eradication group was not as pronounced as that in the successful eradication group.
ATROPHY
The successful eradication group demonstrated a gradual improvement in atrophy of the gastric native epithelium at 6 weeks and 30 weeks after completion of treatment, but, as expected, no major changes were observed in the failed eradication group (Fig. 3 ). Atrophy before treatment was more severe in the failed eradication group than in the successful eradication group.
METAPLASIA
No change in metaplasia was detected following H. pylori eradication therapy, irrespective of the success or failure of treatment (Fig. 4) . In both groups, moderate and marked metaplasia were uncommon in the central antrum while metaplasia of any degree was rare in the upper corpus. Metaplasia before treatment was more severe in the failed eradication group than in the group demonstrating successful eradication.
Discussion
Previously, gastric mucosal atrophy was thought to be associated with ageing, but 
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Mild Moderate Marked some reports on histopathological changes in the stomach following H. pylori eradication have indicated that successful eradication improves gastric mucosal atrophy. 11, 12 Contrary to this view, however, other reports claim no improvement in atrophy despite eradication of H. pylori. 16 Consensus on this issue is therefore yet to be reached.
To elucidate the relationship between H. pylori eradication and gastric cancer it is essential to evaluate the changes in gastric mucosal histology resulting from eradication. 17 In the present study, we examined the changes in gastric mucosal histology after triple eradication therapy in H. pylori-positive patients who had a healed peptic ulcer at study entry.
Improvements in inflammation and neutrophil activity were observed following successful eradication of H. pylori and were maintained 30 weeks after completion of eradication therapy. This favourable situation is believed to be due to a reduction in inflammatory cell infiltration of the gastric mucosa as a result of H. pylori eradication. In the failed eradication group, improvements in inflammation and neutrophil activity observed at 6 weeks were also maintained at 30 weeks, suggesting that a beneficial effect was obtained from a reduction in the presence of H. pylori.
Atrophy in the central antrum and upper corpus was less severe in the successful eradication group and improvement at 30 weeks was greater than at 6 weeks. This suggests that atrophy requires a prolonged period in order to both progress and improve. The gradual improvement in atrophy, a precursor state to gastric cancer, suggests that H. pylori eradication might reduce the risk of gastric cancer.
No improvement in metaplasia was detected, irrespective of success or failure of H. pylori eradication therapy. Further largescale and long-term studies are needed to elucidate whether metaplasia eventually improves after eradication therapy.
When the severity of atrophy and metaplasia before treatment were compared, both were more severe in the failed eradication group. Success or failure of eradication therapy might therefore be affected by the severity of atrophy or metaplasia in the pre-treatment state, or the propensity of H. pylori to further aggravate atrophy and metaplasia.
Conclusions
Improvements in atrophy, inflammation and neutrophil activity were confirmed histopathologically following successful H. pylori eradication therapy, but improvements in inflammation and neutrophil activity were also seen after failed eradication therapy. No improvement in metaplasia was observed, irrespective of the success or failure of treatment. Since atrophy is known to be involved in the aetiology of gastric cancer, H. pylori eradication might prevent development of gastric cancer.
